BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and
BOSTON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company that would be the cause of the recent volatility and decline in
- Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO ® (nivolumab) - - Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology targets - BOSTON, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc.
BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 10 a.m. PST.
— Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty -modified CD19-specific CAR + T cells — — Point-of-care CD19-specific CAR + T cells co-expressing mbIL15 with control switch show sustained persistence, anti-tumor effect in preclinical
— Controlled IL-12 gene therapy turns cold tumors hot — — MRI indicates decreasing size of brain tumor lesions in several patients — — Median overall survival for patients with recurrent glioblastoma (rGBM) maintained at 12.5 months in 20mg cohort with longer follow-up — — Company conference call
BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET.
Company to host conference call today at 4:30 p.m. ET Pivotal, randomized control trial in rGBM to initiate by end of 2017 Combination trial with checkpoint inhibitor in rGBM to initiate by end of 2017 Point-of-care trial with CAR + T cells co-expressing membrane-bound interleukin (mbIL15) to
